Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Authors :: Herbrecht, Raoul
Denning, David W.
Patterson, Thomas F.
Bennett, John E.
Greene, Reginald E.
Oestmann, Jorg-W.
Kern, Winfried V.
Marr, Kieren A.
Ribaud, Patricia
Lortholary, Olivier
Sylvester, Richard
Rubin, Robert H.
Wingard, John R.
Stark, Paul
Durand, Christine
Caillot, Denis
Thiel, Eckhard
Chandraselar, Pranatharthi H.
Hodges, Michael R.
Schlamm, Haran T.
Troke, Peter F.
Pauw, Ben de
Source :: The New England Journal of Medicine. August 8, 2002, Vol. 347 Issue 6, p408, 8 p.
Publication Year :: 2002
Abstract: The antifungal drug voriconazole appears to be more effective than amphotericin B for treating a fungal infection called aspergillosis and has fewer side effects. This was the conclusion of a study of 177 patients who were randomly assigned to receive voriconazole or amphotericin B.

Subjects :: Aspergillosis -- Drug therapy
Antifungal agents -- Evaluation
Amphotericin B -- Evaluation

Tools